K

Kenai Therapeutics

Allogeneic iPSC-derived dopamine neuron therapy

Scientist – Molecular Biology

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSan Diego, CA, USA$110k - $135k /yrIn-person

About the Job

Requirements

  • A Ph.D. in Immunology, Cell Biology, Neuroscience, or a related field with 2–3 years of relevant analytical development industry experience, or an M.S. with 6+ years of relevant analytical development industry experience.
  • Strong analytical skills and deep expertise in molecular biology assay development techniques, analysis, and data interpretation.
  • Hands-on experience handling suspension and adherent mammalian cell cultures and operating in a biological safety cabinet.
  • Strong understanding of ICH guidelines for analytical method development, validation, and phase-appropriate method lifecycle management.
  • Extensive experience operating and maintaining advanced PCR, spectroscopic, and molecular instruments, including Qiagen, ThermoFisher, and Bio-Rad platforms, and associated software such as QuantStudio, QX Manager, and Quantasoft for operations and data analysis.
  • Familiarity with advanced statistical approaches for assay development and validation using JMP, Prism, or equivalent tools.
  • Scientific technical writing skills.
  • Good understanding of cell therapy product development and characterization.
  • Ability to work independently, organize and manage time, and balance multiple tasks and projects.
  • Ability to analyze and communicate scientific findings and development rationale.
  • Ability to work in a small, fast-paced, cross-functional environment.

Responsibilities

  • Lead design, development, and qualification or validation of molecular biology assays such as ddPCR and qPCR.
  • Independently design, plan, troubleshoot, and execute laboratory activities, including instrument setup, sample preparation, assay execution, and data analysis using industry-standard software.
  • Maintain and manage cell lines and cell banks used in analytical assay development.
  • Implement scientifically sound design strategies and establish standardized work templates.
  • Design and perform phase-appropriate assay robustness studies in accordance with regulatory guidelines.
  • Generate, analyze, interpret, and present scientific data in cross-functional meetings.
  • Maintain detailed records of laboratory work, reported results, and data interpretation using electronic lab notebooks.
  • Apply statistical data analysis techniques using JMP, GraphPad Prism, or similar tools to support experimental design and data interpretation.
  • Prepare assay development and technical reports, protocols, standard operating procedures, and other relevant documents using industry-standard documentation practices.
  • Conduct risk and gap assessments for method development and optimization at various phases of the program lifecycle.
  • Ensure assays are fit for purpose and aligned with phase-appropriate regulatory expectations by applying regulatory principles relevant to cell therapy analytical development and validation.
  • Keep current with relevant scientific literature and new technologies or capabilities, and support implementation as appropriate.
  • Partner with Process Development, Quality, Research teams, and external CROs and vendors to ensure analytical readiness for clinical milestones.
  • Support assay method transfers, qualification, and validation in GMP environments for drug product release and lifecycle management.

Desired Qualifications

  • Experience supporting clinical programs from early phase through commercialization.
  • Work experience with mammalian cell culture, flow cytometry assays, and cell-based assays.
  • Experience transferring assays between CDMOs, CROs, and internal teams.
  • Prior experience in a startup or early-phase biotech environment.

About the Company

Kenai Therapeutics

Allogeneic iPSC-derived dopamine neuron therapy

Kenai Therapeutics develops allogeneic iPSC-based cell therapies for neurological disorders, with a focus on Parkinson’s disease. Its lead product, RNDP-001, uses donor-derived induced pluripotent stem cells to create dopamine progenitor cells that can be transplanted to replace lost dopamine neurons in the brain, providing an “off-the-shelf” treatment option rather than patient-specific cells. The company also builds a drug-discovery platform that uses its iPSC technology to create human models for identifying and testing new therapies. Unlike some rivals that rely on autologous cells, Kenai aims to offer scalable, broadly applicable therapies that can be produced in batches and used across many patients, complemented by validation in preclinical and clinical trials to obtain regulatory approval. Its goal is to bring safe, effective cell therapies and related drug candidates to market to improve outcomes for people with neurology disorders, starting with Parkinson’s disease.

Company size
11-50
Company stage
Grant
Total funding
$97M
Headquarters
San Diego, CA
Founded
2022

Recently Posted Jobs

Explore more opportunities at Kenai Therapeutics

See more jobs